translated from Spanish: What about HIV treatment? This says the IMSS

The Mexican Social Security Institute (IMSS) explained on Tuesday that the lack of antiretroviral drugs (ARVs) in its inventories, necessary for HIV patients, was an “atypical situation” caused by the interruption in the production of the drug Truvada®.
This drug was until November the main component of the ARV treatment line used in IMSS.
To ensure the delivery of medicines, the dependence stated that a change is made to the scheme of those patients who are candidates to replace the treatment Efavirenz+Truvada® with the drug Biktarvy® (Bictegravir/ Emtricitabine/Tenofovir).
The Institute mentions that this substitution reduces treatment to a daily pill and facilitates its adherence. He also stated that “Biktarvy’s supply® is guaranteed in all IMSS medical units.”
In the case of rightholders who are not candidates to migrate to the new drug, the institute explained that “ARV drugs containing the same compounds as Truvada® (Emtricitabine and Tenofovir) have been acquired”.
It stated that “there are sufficient stocks of Uncoformulated Emtricitabine and Tenofovir, which strengthens the supply of ARV medicines.”
In view of these facts, the IMSS asks the rightholders who are under ARV treatment to contact their specialist doctor as soon as possible, to replace their prescriptions or be reassessed to replace their treatment. 
Report lack of medication 
In April, HIV patients receiving care in hospitals at the Ministry of Health reported that the new mechanism for purchasing medicines led to the desabate of retroviral treatments.
Until November, social media users continued to report a lack of medicines. 

URGENT REPORTING: Desabasto of retroviral drugs for HIV/AIDS in @Tu_IMSS There is no refusal to supply prescriptions in Pharmacy of Clinic 1 of the @Ezequie79417285 @IMSS_DURANGO @Ezequie79417285 @tadeocampagne Report @censida @JavTe @baruchdom @baruchdom @fernandoleon61 @azucenau @tudyssex @tudyssex pic.twitter.com/Hf69t6gMhX
— Dan Santos (@DanSantosMX) November 5, 2019

Previously the tendering and purchase of these medicines was the responsibility of the National Center for the Prevention and Control of HIV/AIDS (Censida), but now, at the mandate of President Andrés Manuel López Obrador, the process depends on the Ministry of Health in coordination with the Ministry of Finance and Public Credit.
What we do in Animal Político requires professional journalists, teamwork, dialogue with readers and something very important: independence. You can help us keep going. Be part of the team.
Subscribe to Animal Politician, receive benefits and support free journalism.#YoSoyAnimal

Original source in Spanish

Related Posts

Add Comment